|
ESOPHAGEAL
Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma (CALGB 80101):
- Patients must have pathologically confirmed adenocarcinoma of the stomach or gastroesophageal junction
- Adenocarcinomas of the esophagus that are not involving the gastroesophageal junction are not eligible
- Patients must have had a total resection of all known tumor
- Patient must not have metastatic disease
RECTAL
Treatment with Two Chemotherapy Drugs Combined with Radiation Therapy for Patients with Rectal Cancer (NSABP R-04):
- Diagnosis of invasive rectal cancer
- Biopsy only of the tumor, no resection
- Tumor must be palpable by rectal exam
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with State II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (ECOG E5202):
- No history of isolated, distant, or non-contiguous intra-abdominal metastases, even if restricted
- Histologically confirmed adenocarcinoma of the colon
- Patients must have > 8 lymph nodes evaluated and reported
- Must not have presented with complete obstruction or perforation of the bowel
- Patients must not have had any systemic or radiation therapy initiated for this malignancy
|
